Why drug-price shaming hasn't hurt
Jeff Aronin with investors
|
|
Paragon's
popularity illustrates the power of a lucrative business model based on high
prices for drugs that treat rare diseases.
|
Why drug-price shaming hasn't hurt
Jeff Aronin with investors
|
|
Paragon's
popularity illustrates the power of a lucrative business model based on high
prices for drugs that treat rare diseases.
|
No comments:
Post a Comment